Cancer remains one of the most strong challenges existing in modern medicine as of today, making it necessary to innovate strategies to combat its relentless progression. Out of the many strategies ...

Breast cancer, the most common cancer among women, is notorious for its ability to develop resistance to a wide range of treatments, including surgery, chemotherapy, targeted therapies, and ...

The field of tumor microenvironment research has increasingly highlighted the intertwined relationship between aberrant vasculature and dysregulated immune ...

Angiogenesis inhibitors showed no increased risk of arterial dissections or aneurysms in metastatic colorectal cancer patients. The study involved 34,733 patients, with 195 cases matched to 1950 ...

Pitavastatin, a cholesterol lowering drug, slashes chemotherapy resistance in breast cancer by obstructing a specific protein ...

Researchers from Washington University School of Medicine performed studies to assess the role of ZBTB46, a repressive transcription factor and a marker for classical dendritic cells (DCs), in tumor ...

FDA has announced it has approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal ...

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor ...

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and ...